A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: 6.0 mg/kg of TQB2102 for injection|DRUG: 7.5 mg/kg of TQB2102 for injection
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.